Formulary and support resources
Resources to support you with your decision making and implementation of EYLEA® (aflibercept) 8 mg for the treatment of neovascular (wet) age-related macular degeneration (nAMD) in adults and the treatment of visual impairment due to diabetic macular oedema (DMO) in adults.
EYLEA 8 mg represents a line extension from the currently available EYLEA 2 mg dose.
An updated statement from NICE here states that
As it is a line extension, implementation of EYLEA 8 mg may differ between local health systems. This page contains resources to support your formulary update activities across a range of likely scenarios.
FORMULARY GUIDES
Click below to view guides based on the
All of the information you might require regarding
ADDITIONAL RESOURCES
Click below to view the
